This article discusses the results of a study on the use of the immune checkpoint inhibitor durvalumab in patients with triple-negative breast cancer (TNBC). The study found that higher levels of CD4+ T cells before treatment and an expansion of γδ T cells during treatment were associated with a better response to durvalumab. The study also examined changes in immune cell composition during treatment and found that a decrease in certain immune cell populations and an increase in γδ T cells correlated with a higher rate of pathological complete response (pCR) to durvalumab. The authors suggest that these findings could potentially be used as biomarkers to predict patient response to durvalumab, but further research is needed to validate these results. [Extracted from the article]